These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38751324)

  • 1. The Association between Oxaliplatin-Induced Peripheral Neuropathy, Sociodemographic, and Clinical Characteristics with Falls in Older Adults with Colorectal Cancer.
    Hines RB; Schoborg C; Sumner T; Thiesfeldt DL; Zhang S
    Am J Epidemiol; 2024 May; ():. PubMed ID: 38751324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association between sociodemographic, clinical, and potentially preventive therapies with oxaliplatin-induced peripheral neuropathy in colorectal cancer patients.
    Hines RB; Schoborg C; Sumner T; Zhu X; Elgin EA; Zhang S
    Support Care Cancer; 2023 Jun; 31(7):386. PubMed ID: 37294347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer.
    Griffith KA; Zhu S; Johantgen M; Kessler MD; Renn C; Beutler AS; Kanwar R; Ambulos N; Cavaletti G; Bruna J; Briani C; Argyriou AA; Kalofonos HP; Yerges-Armstrong LM; Dorsey SG
    J Pain Symptom Manage; 2017 Nov; 54(5):701-706.e1. PubMed ID: 28743660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study protocol: fish oil supplement in prevention of oxaliplatin-induced peripheral neuropathy in adjuvant colorectal cancer patients - a randomized controlled trial. (OxaNeuro).
    Gehr NL; Karlsson P; Timm S; Christensen S; Hvid CA; Peric J; Hansen TF; Lauritzen L; Finnerup NB; Ventzel L
    BMC Cancer; 2024 Feb; 24(1):168. PubMed ID: 38308227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in chemotherapy-induced peripheral neuropathy, disturbance in activities of daily living, and depression following chemotherapy in patients with colorectal cancer: A prospective study.
    Oh PJ; Lee JR; Kim SK; Kim JH
    Eur J Oncol Nurs; 2020 Feb; 44():101676. PubMed ID: 31751847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients.
    Nagashima M; Ooshiro M; Moriyama A; Sugishita Y; Kadoya K; Sato A; Kitahara T; Takagi R; Urita T; Yoshida Y; Tanaka H; Oshiro T; Okazumi S; Katoh R
    Support Care Cancer; 2014 Jun; 22(6):1579-84. PubMed ID: 24452412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of traditional plant-based medicines for preventing chronic oxaliplatin-induced peripheral neurotoxicity in patients with colorectal cancer: A systematic review and meta-analysis with core herb contribution.
    Han J; Lai H; Li W; Liao H; Xiao C; Li X; You F; Guo J
    J Ethnopharmacol; 2024 May; 326():117735. PubMed ID: 38211824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment.
    Kang L; Tian Y; Xu S; Chen H
    J Neurol; 2021 Sep; 268(9):3269-3282. PubMed ID: 32474658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Prospective Study of Chronic Oxaliplatin-Induced Neuropathy in Patients with Colon Cancer: Long-Term Outcomes and Predictors of Severe Oxaliplatin-Induced Neuropathy.
    Kim SH; Kim W; Kim JH; Woo MK; Baek JY; Kim SY; Chung SH; Kim HJ
    J Clin Neurol; 2018 Jan; 14(1):81-89. PubMed ID: 29629544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702.
    Lee S; Ma C; Shi Q; Kumar P; Couture F; Kuebler P; Krishnamurthi S; Lewis D; Tan B; Goldberg RM; Venook A; Blanke C; O'Reilly EM; Shields AF; Meyerhardt JA
    J Clin Oncol; 2023 Feb; 41(5):1079-1091. PubMed ID: 36367997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time-dependent discrepancies between physician-assessed and patient-reported oxaliplatin-induced peripheral neuropathy in patients with metastatic colorectal cancer who received mFOLFOX6 plus bevacizumab: a post hoc analysis (WJOG4407GSS2).
    Miura Y; Ando M; Yamazaki K; Hironaka S; Boku N; Muro K; Hyodo I
    Support Care Cancer; 2021 Jul; 29(7):3715-3723. PubMed ID: 33200233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathological Mechanisms and Preventive Strategies of Oxaliplatin-Induced Peripheral Neuropathy.
    Egashira N
    Front Pain Res (Lausanne); 2021; 2():804260. PubMed ID: 35295491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of the Motivational Interviewing-Walk Intervention for Chemotherapy-Induced Peripheral Neuropathy and Quality of Life During Oxaliplatin Treatment: A Pilot Randomized Controlled Trial.
    Kanzawa-Lee GA; Ploutz-Snyder RJ; Larson JL; Krauss JC; Resnicow K; Lavoie Smith EM
    Cancer Nurs; 2022 Mar-Apr 01; 45(2):E531-E544. PubMed ID: 34483279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS Supportive Care intergroup.
    Kerckhove N; Busserolles J; Stanbury T; Pereira B; Plence V; Bonnetain F; Krakowski I; Eschalier A; Pezet D; Balayssac D
    BMJ Open; 2019 Jun; 9(6):e027770. PubMed ID: 31182448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized controlled trial of hand/foot-cooling by hilotherapy to prevent oxaliplatin-related peripheral neuropathy in patients with malignancies of the digestive system.
    Coolbrandt A; Tobback H; Govaerts R; Vandezande L; Vinckx M; Laenen A; Wildiers H; Verslype C; Dekervel J; Van Herpe F; Van Cutsem E
    ESMO Open; 2023 Apr; 8(2):101205. PubMed ID: 37018872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monosialotetrahexosylganglioside in the treatment of chronic oxaliplatin-induced peripheral neurotoxicity: TJMUCH-GI-001, a randomised controlled trial.
    Zhou L; Liu R; Huang D; Li H; Ning T; Zhang L; Ge S; Bai M; Wang X; Yang Y; Wang X; Chen X; Gao Z; Luo L; Yang Y; Wu X; Deng T; Ba Y
    EClinicalMedicine; 2021 Nov; 41():101157. PubMed ID: 34765950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of donepezil for the treatment of oxaliplatin-induced peripheral neuropathy: DONEPEZOX, a protocol of a proof of concept, randomised, triple-blinded and multicentre trial.
    Kerckhove N; Tougeron D; Lepage C; Pezet D; Le Malicot K; Pelkowski M; Pereira B; Balayssac D
    BMC Cancer; 2022 Jul; 22(1):742. PubMed ID: 35799138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Class I HDAC Inhibitor, MS-275, Prevents Oxaliplatin-Induced Chronic Neuropathy and Potentiates Its Antiproliferative Activity in Mice.
    Lamoine S; Cumenal M; Barriere DA; Pereira V; Fereyrolles M; Prival L; Barbier J; Boudieu L; Brasset E; Bertin B; Renaud Y; Miot-Noirault E; Civiale MA; Balayssac D; Aissouni Y; Eschalier A; Busserolles J
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Huangqi Guizhi Wuwu Decoction for Oxaliplatin-Induced Peripheral Neurotoxicity: A Systematic Review and Meta-Analysis.
    Yu J; Chen S; Wei G; Gu J; Huo J; Ding R; Li L
    Altern Ther Health Med; 2024 Jan; 30(1):446-453. PubMed ID: 37820675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development.
    Yang Y; Zhao B; Gao X; Sun J; Ye J; Li J; Cao P
    J Exp Clin Cancer Res; 2021 Oct; 40(1):331. PubMed ID: 34686205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.